Bristol Myers Squibb (BMY) Intangibles (2009 - 2026)

Bristol Myers Squibb has disclosed Intangibles across 18 years of filings, most recently posting $18.2 billion for Q1 2026.

• In Q1 2026, Intangibles fell 18.87% year-over-year to $18.2 billion; the TTM figure through Mar 2026 stood at $18.2 billion (down 18.87% YoY), while the FY2025 annual figure was $19.1 billion, down 18.04% from the prior year.
• Intangibles retreated to $18.2 billion in Q1 2026, from $19.1 billion in the prior quarter.
• Over the last five years, Intangibles for BMY reached as high as $40.1 billion in Q1 2022 and fell as low as $18.2 billion in Q1 2026.
• The 5-year median for Intangibles is $29.0 billion (2023), against an average of $28.6 billion.
• Annual changes were most pronounced in 2024 — Intangibles retreated 2.41% — and 2025, when it slumped 31.36%.
• A 5-year view of Intangibles shows it stood at $35.9 billion in 2022, then retreated by 24.5% to $27.1 billion in 2023, then dropped by 13.91% to $23.3 billion in 2024, then dropped by 18.04% to $19.1 billion in 2025, then declined by 4.5% to $18.2 billion in 2026.
• According to Business Quant data, Intangibles over the past three periods registered $18.2 billion, $19.1 billion, and $20.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.